Myelitis, Transverse: Clinical Trials

42 trials for Myelitis, Transverse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 8 recruiting, 4 active not recruiting, 4 unknown. 42 Phase 2, 13 Phase 1, 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 242Completed 17, Recruiting 8, Active not recruiting 4, Unknown 4, Not yet recruiting 3, Terminated 3, Withdrawn 3
Phase 113Completed 5, Recruiting 3, Not yet recruiting 2, Unknown 2, Terminated 1
Phase 39Completed 3, Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1

Follow Myelitis, Transverse: new trials by email Literature Review of Myelitis, Transverse trials Research Report on Myelitis, Transverse

Trials (filtered) newest first · largest first

All 42 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle
Phase 2WithdrawnMichael, Levy M.D.,Ph.D.2026-12-312025-07-16
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2Not yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
Phase 1 / Phase 2Not yet recruitingCRISPR Therapeutics2202026-11-012026-10-22
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 2Not yet recruitingPeking University People's Hospital602026-08-302026-09-09
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor - Neuromyelitis Optica Spectrum Disorder Attack
Phase 2Active not recruitingTianjin Medical University General Hospital1102025-09-092026-06-03
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Complement protein C5 inhibitor, IVMP - Neuromyelitis Optica Spectrum Disorder Attack
Phase 2WithdrawnTianjin Medical University General Hospital2025-09-032025-09-10
Efgartigimod for the Treatment of Acute Optic Neuritis
Efgartigimod Alfa, Placebo - Optic Neuritis
Phase 2RecruitingAnastasia Vishnevetsky, MD, MPH202025-08-122026-10-28
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Phase 1 / Phase 2RecruitingTianjin Medical University General Hospital272025-04-102026-10-16
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
IMC-002, mycophenolate mofetil, MMF - Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 1 / Phase 2UnknownImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.1162024-10-102024-08-16
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
B001, Placebo - Neuromyelitis Optica Spectrum Disorders
Phase 2 / Phase 3RecruitingShanghai Jiaolian Drug Research and Development Co., Ltd1322024-07-172026-05-05
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Phase 2UnknownTianjin Medical University General Hospital632024-07-052024-07-11
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Inebilizumab - Neuromyelitis Optica Spectrum Disorder
Phase 2RecruitingAmgen152023-07-032025-12-05
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids - Neuromyelitis Optica Spectrum Disorders
Phase 2RecruitingGuangzhou JOYO Pharma Co., Ltd352023-05-242024-11-20
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mitoxantrone Hydrochloride Liposome Injection - Neuromyelitis Optica Spectrum Disorder
Phase 2CompletedCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.462022-11-282024-08-07
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3Active not recruitingTianjin Medical University General Hospital1352022-11-012025-03-30
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Vibegron - Neurogenic Detrusor Overactivity
Phase 2 / Phase 3RecruitingUrovant Sciences GmbH712022-10-122026-06-15
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
Q-Cells - Transverse Myelitis
Phase 1 / Phase 2RecruitingQ Therapeutics, Inc.92022-09-202026-07-21
Ofatumumab in AQP4-IgG Seropositive NMOSD
Ofatumumab - Neuromyelitis Optica Spectrum Disorder
Phase 1 / Phase 2RecruitingTang-Du Hospital52022-06-282026-01-30
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Ravulizumab - Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.122022-06-232026-06-24
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
zanubrutinib - Neuromyelitis Optica
Phase 2TerminatedXuanwu Hospital, Beijing62022-05-072026-04-27

Showing 20 of 42. Sign in to see all of them.

Narrower conditions

Neuromyelitis Optica (39)  ·  Demyelinating Diseases (3)  ·  Multiple Sclerosis (3)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Multiple Sclerosis, Chronic Progressive (2)  ·  Myasthenia Gravis (2)  ·  Optic Neuritis (2)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2)  ·  Spinal Cord Injuries (2)  ·  Stiff-Person Syndrome (2)  ·  Autoimmune Diseases (1)  ·  Diffuse Cerebral Sclerosis of Schilder (1)  ·  Lambert-Eaton Myasthenic Syndrome (1)  ·  Marijuana Abuse (1)

Broader conditions

Demyelinating Autoimmune Diseases, CNS (42)  ·  Immune System Diseases (42)  ·  Nervous System Diseases (42)  ·  Autoimmune Diseases (41)  ·  Autoimmune Diseases of the Nervous System (40)  ·  Cranial Nerve Diseases (39)  ·  Demyelinating Diseases (39)  ·  Eye Diseases (39)  ·  Optic Nerve Diseases (39)  ·  Optic Neuritis (37)  ·  Central Nervous System Diseases (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Neoplasms (7)  ·  Neoplasms by Site (7)

Interventions

Methylprednisolone (4)  ·  eculizumab (4)  ·  Antilymphocyte Serum (3)  ·  Rituximab (3)  ·  thymoglobulin (3)  ·  Azathioprine (2)  ·  Cyclophosphamide (2)  ·  Filgrastim (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  Immunoglobulins, Intravenous (2)  ·  Mesna (2)  ·  Methylprednisolone Acetate (2)  ·  Methylprednisolone Hemisuccinate (2)  ·  Prednisone (2)  ·  efgartigimod alfa (2)

Sponsors

Tianjin Medical University General Hospital (10)  ·  Alexion Pharmaceuticals, Inc. (2)  ·  Northwestern University (2)  ·  Amgen (1)  ·  Anastasia Vishnevetsky, MD, MPH (1)  ·  Buckinghamshire Healthcare NHS Trust (1)  ·  CRISPR Therapeutics (1)  ·  CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Fu-Dong Shi (1)  ·  Guangzhou JOYO Pharma Co., Ltd (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. (1)  ·  Isfahan University of Medical Sciences (1)  ·  Johns Hopkins University (1)

Countries

China (16)  ·  United States (16)  ·  Canada (7)  ·  Spain (5)  ·  Japan (4)  ·  Poland (4)  ·  Germany (3)  ·  Italy (3)  ·  Serbia (3)  ·  South Korea (3)  ·  Turkey (Türkiye) (3)  ·  France (2)  ·  Hungary (2)  ·  Russia (2)  ·  United Kingdom (2)

Top investigators

Fu-Dong Shi, MD,PhD (3)  ·  Michael Levy, MD, PhD (3)  ·  Richard Burt, MD (2)  ·  Anastasia Vishnevetsky, MD, MPH (1)  ·  Anastasia Vishnevetsky, MD, PhD (1)  ·  Benjamin Greenberg, MD (1)  ·  Ilana Katz Sand, MD (1)  ·  Jan Storek, MD,PhD (1)  ·  Janet Owens-Grillo (1)  ·  Jodie M Burton, MD,MSc,FRCPC (1)  ·  Jun Guo, M.D. (1)  ·  Junwei Hao, MD (1)  ·  Leona Holmberg (1)  ·  Maurizio Belci, DMS MSc MRCS FRCP (1)

Results publications

PMID 23623397, PMID 23764350, PMID 26083135, PMID 26666258, PMID 28831548, PMID 31495497, PMID 32333897, PMID 33538237, PMID 33724534, PMID 33771837, PMID 35158461, PMID 36370634, PMID 37221052, PMID 38760098, PMID 39222408, PMID 39651334

NIH funding

2008 (1), 2014 (1), 2019 (1), 2023 (1)